GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Insider Ownership

Mesoblast (Mesoblast) Insider Ownership : 0.00 % (As of Apr. 28, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Mesoblast's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Mesoblast's Institutional Ownership is 9.46%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Mesoblast's Float Percentage Of Total Shares Outstanding is 82.76%.


Mesoblast Insider Ownership Historical Data

The historical data trend for Mesoblast's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Insider Ownership Chart

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Mesoblast Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Mesoblast Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Mesoblast (Mesoblast) Business Description

Traded in Other Exchanges
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.